Similarly, the PFS of patients with advanced triple-negative breast cancer treated with PDCD1/CD274 inhibitors combined with chemotherapy was longer than those treated with chemotherapy alone [27]. The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.